31 results about "Affinity constant" patented technology

The invention relates to the technical field of immunological detection methods, in particular to an antibody of a human Golgi apparatus membrane protein GP73, an antibody composition and application. The antibody provided by the invention has a relatively high relative affinity constant with a human Golgi apparatus membrane protein GP73, can be combined with a target protein with high sensitivity and high specificity, and has relatively high stability; based on the antibody, the invention provides a method for detecting the human Golgi body membrane protein GP73 by using a double-antibody sandwich ELISA (Enzyme-Linked Immunosorbent Assay) method, the content of the human Golgi body membrane protein GP73 in serum or related products can be accurately and quickly detected on a large scale, and the antibody has a relatively good application prospect in the detection of the content of the human Golgi body membrane protein GP73.

The present invention relates to the technical field of immunological detection methods, and in particular to an antibody, antibody composition and application of human Golgi membrane protein GP73. The antibody provided by the present invention has a high relative affinity constant with human Golgi membrane protein GP73, can bind to the target protein with high sensitivity and high specificity, and has high stability; based on the antibody, the present invention provides a method for detecting human Golgi membrane protein GP73 using a double antibody sandwich ELISA method, which can accurately, quickly and in large quantities detect the content of human Golgi membrane protein GP73 in serum or related products, and has good application prospects in the content detection of human Golgi membrane protein GP73.

The invention relates to the technical field of biology, and particularly discloses a cronobacter sakazakii nucleic acid aptamer and application thereof in preparation of a biosensor. According to the invention, a nucleic acid aptamer with a DNA sequence as shown in SEQ ID No: 1 is designed for Cronobacter sakazakii MipA protein, and 5'terminal amino is modified. The aptamer can be used for constructing a fluorescence quenching type biosensor, and comprises a fluorescent probe (fluorescent nanoparticles synthesized by citric acid diammonium, thiourea, tetramethyl orthosilicate and cerium dioxide, and a first aptamer modified by carboxyl) and a quenching probe (citric acid reduced gold nanoparticles, a second aptamer modified by sulfydryl, SEQ ID No: 2). Compared with a traditional method, the screening efficiency is remarkably improved, and the detection time is lt; the method has the advantages of high sensitivity, high interference resistance and affinity constant of 13.28 nM, is suitable for rapid monitoring of infant food, and reduces the economic cost by at least 40%.

The application provides an anti-aflatoxin B1 monoclonal antibody and application, and particularly relates to an anti-aflatoxin B1 monoclonal antibody containing only a heavy chain variable region, a nucleotide coding the antibody, an expression vector carrying the monoclonal antibody or a nucleotide sequence coding the monoclonal antibody. The application screens and prepares an antibody for aflatoxin B1 from a phage nanobody synthesis library and applies the antibody to detection or identification of aflatoxin B1. The affinity constant of the antibody is 1.96E-07, the antibody can effectively detect aflatoxin B1, and can be identified from other common fungal toxins.

The present application relates to an assay method using affinity crosslinking of DNA-linked ligands to proteins to enable small molecule screening and determination of apparent affinity constants of ligands to the proteins. This method has been applied to determine 96 compounds' dissociation constants to a protein target simultaneously, and directly determine a compound's IC50 against five protein targets concurrently in crude cell lysates. Additionally, this approach was used to screen a Library of Pharmacologically Active Compounds (LOPAC) library against dihydrofolate reductase (eDHFR), enabling the discovery of a novel eDHFR inhibitor (IC50=7.9 μM). An assay kit and the method of uses are within the scope of this disclosure.

The application is based on machine learning model, and the polypeptide WFKDWY (166953) with potential is screened through polypeptide virtual screening technology based on the analysis of PEDV Nsp5 protein crystal structure. The sequence of 166953 is artificially synthesized by solid phase, and the polypeptide is screened by using artificially expressed PEDV Nsp5 protein through ELISA experiment. The affinity constant of the polypeptide and the target protein is identified by surface plasmon resonance experiment (SPR). The cytotoxicity of the polypeptide 166953 is tested by CCK-8 kit. The virus infection inhibiting activity of the polypeptide is tested by fluorescence quantitative PCR and indirect immunofluorescence experiment. The results show that the sequence 166953 can significantly inhibit the infection of PEDV.

This invention utilizes a machine learning model to analyze the crystal structure of the PEDV Nsp5 protein. Through virtual peptide screening technology, a peptide sequence with potential affinity for the target protein, YKKLHK(162860), was artificially synthesized in a solid phase. Using artificially expressed PEDV Nsp5 protein, the peptide was screened using an ELISA assay. The affinity constant between the peptide and the target protein was determined using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 162860 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was tested using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that the 162860 sequence significantly inhibited PEDV infection.

The application is used for analyzing the S1-CTD region of the PEDV S protein crystal structure by means of a machine learning model, and a polypeptide sequence FWKSKR (110766) with potential is screened from the target protein by polypeptide virtual screening technology. The 110766 sequence is artificially synthesized on a solid phase, and the polypeptide is screened by means of ELISA experiment using artificially expressed PEDV S1 protein. The affinity constant of the polypeptide and the target protein is identified by means of surface plasmon resonance experiment (SPR). The cytotoxicity of the polypeptide 110766 is tested by CCK-8 kit. The virus infection inhibiting activity of the polypeptide is tested by means of fluorescent quantitative PCR and indirect immunofluorescence experiment. The results show that the 110766 sequence can significantly inhibit the infection of PEDV.

The invention discloses a method for identifying chiral triazole bactericides by using P38 protein, the affinity constant of unknown triazole bactericide monomers and P38 protein is measured by a surface plasmon resonance technology, and the affinity constant is compared with the affinity constant of a standard substance, so that the configuration of the unknown monomers is judged. The detection method is simple.

The invention provides a polypeptide variant based on ARC protein and application of the polypeptide variant as a nucleic acid delivery carrier, the polypeptide variant based on ARC protein is a variant based on spatial conformation, amino acid point mutation and side chain modification of a lipid group or a lipid group derivative, the spatial conformation is alpha helix, and the amino acid point mutation is alpha helix. The target of the point mutation is to increase the isoelectric point to 10.0 or above. The polypeptide variant has an excellent affinity constant of nucleic acid, can wrap mRNA or DNA and form a structure similar to a virus capsid, not only can protect mRNA from being degraded by nuclease, but also is helpful for releasing mRNA or DNA under the action of lysosome / endosome after a mediating compound enters cells, and can activate and generate effective body fluid and cellular immune response in vivo, so that the polypeptide variant has the advantages of being capable of effectively improving the immunogenicity of the cells and improving the immunogenicity of the cells. The polypeptide has obvious immune protection on rat pox challenge and melanoma, and has good biocompatibility, so that the polypeptide can be prepared into a novel nucleic acid delivery carrier based on bionic polypeptide.

This invention utilizes a machine learning model to analyze the S1-CTD region of the PEDV S protein crystal structure. Through virtual peptide screening, a peptide sequence of FWKEAK (110616) with potential affinity for the target protein was identified. The 110616 sequence was artificially synthesized in a solid phase, and the peptide was screened using ELISA with artificially expressed PEDV S1 protein. The affinity constant between the peptide and the target protein was determined using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 110616 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was assessed using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that the 110616 sequence significantly inhibited PEDV infection.

The invention discloses a modeling method for the binding affinity difference between annexin A5AnxA5 and fluorescent protein FPs and phosphatidylserine PS caused by fusion of annexin A5AnxA5 and fluorescent protein FPs and application of the modeling method. 18 kinds of binding conditions of AnxA5 based on fluorescent protein and apoptotic cells are detected through flow cytometry, and the binding affinity between AnxA5-FPs fusion protein and phosphatidylserine PS is obtained through data analysis; the PS affinity of the fusion protein is different, and the affinity constant Kd of the fusion protein with the highest PS affinity and the affinity constant Kd of the fusion protein with the lowest PS affinity are different by more than two orders of magnitude. The aggregation characteristic of the fluorescent protein is a factor influencing the PS affinity of the fusion protein; different fluorescent proteins and AnxA5 are subjected to fusion expression to generate different conformations, and the difference on the conformations causes the fusion proteins to have different PS binding modes, so that the difference of PS binding affinity is shown.

The invention belongs to the field of tumor screening reagents, and particularly discloses a broad-spectrum tumor screening kit for a carcino-embryonic antigen (CEA) and a preparation method of the broad-spectrum tumor screening kit. The kit comprises a solid phase carrier coated with a high-affinity mouse anti-human CEA monoclonal antibody, a horse radish peroxidase labeled goat anti-human CEA polyclonal antibody, a chemiluminescent substrate solution, a calibration product and a quality control product. The preparation method is characterized in that antibody pairs which are high in affinity and capable of recognizing different epitopes are adopted, and the antibody pairs are prepared through the processes of optimized coating, enzyme labeling and freeze drying. The core of the invention lies in that the affinity constant KD value is less than 1 * 10 < M > when the antibody pair is used in compatibility, and a chemiluminescence detection system is adopted. The kit has ultrahigh sensitivity, wide linear range and excellent stability, can accurately quantify low-concentration and high-concentration CEA in human serum, effectively avoids the hook effect, is suitable for early screening, curative effect monitoring and prognosis evaluation of various malignant tumors such as colorectal cancer, lung cancer and the like, and has the detection performance obviously superior to that of a traditional ELISA kit.

Disclosed herein are fully human antibody molecules that immunospecifically bind to human IL-5. The antibody molecules can bind to human IL-5 with an equilibrium affinity constant (KD) of at least about 40 pM as determined by surface plasmon resonance.

The invention relates to the technical field of immunological detection methods, in particular to an antibody of a human Golgi apparatus membrane protein GP73, an antibody composition and application. The antibody provided by the invention has a relatively high relative affinity constant with a human Golgi apparatus membrane protein GP73, can be combined with a target protein with high sensitivity and high specificity, and has relatively high stability; based on the antibody, the invention provides a method for detecting the human Golgi body membrane protein GP73 by using a double-antibody sandwich ELISA (Enzyme-Linked Immunosorbent Assay) method, the content of the human Golgi body membrane protein GP73 in serum or related products can be accurately and quickly detected on a large scale, and the antibody has a relatively good application prospect in the detection of the content of the human Golgi body membrane protein GP73.

This invention utilizes a machine learning model to analyze the crystal structure of the PEDV Nsp5 protein. Through virtual peptide screening, a peptide sequence KYRRQH (177080) with potential affinity for the target protein was identified. The 177080 sequence was artificially synthesized in a solid phase, and the peptide was screened using ELISA with artificially expressed PEDV Nsp5 protein. The affinity constant between the peptide and the target protein was determined using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 177080 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was assessed using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that 177080 significantly inhibited PEDV infection.

The present invention relates to the technical field of immunological detection methods, and in particular to an antibody, antibody composition and application of human Golgi membrane protein GP73. The antibody provided by the present invention has a high relative affinity constant with human Golgi membrane protein GP73, can bind to the target protein with high sensitivity and high specificity, and has high stability; based on the antibody, the present invention provides a method for detecting human Golgi membrane protein GP73 using a double antibody sandwich ELISA method, which can accurately, quickly and in large quantities detect the content of human Golgi membrane protein GP73 in serum or related products, and has good application prospects in the content detection of human Golgi membrane protein GP73.

The invention discloses a nucleic acid aptamer of RUNX2 protein and application of the nucleic acid aptamer, and belongs to the technical field of biology, the nucleotide sequence of the nucleic acid aptamer is shown as SEQ ID NO.1, the nucleic acid aptamer has the advantages of being small in molecular weight, stable in chemical property, easy to store and mark and the like, the nucleic acid aptamer is obtained through screening based on the SELEX technology, the nucleic acid aptamer can be combined with the RUNX2 protein with high affinity and high specificity, and the nucleic acid aptamer can be used for detecting the RUNX2 protein. The affinity constant is as low as 8.88 nM, and the synthesis cost is low. The nucleic acid aptamer provided by the invention shows good application prospects in the aspects of disease detection, diagnosis, molecular imaging, targeted therapy and the like.

The application is based on machine learning model, and the polypeptide RFFMWH (170849) with potential is screened through polypeptide virtual screening technology based on the analysis of PEDV Nsp5 protein crystal structure. The sequence of 170849 is artificially synthesized, and the polypeptide is screened by using artificially expressed PEDV Nsp5 protein through ELISA experiment. The affinity constant of the polypeptide and the target protein is identified by surface plasmon resonance experiment (SPR). The cytotoxicity of the polypeptide 170849 is tested by CCK-8 kit. The virus infection inhibiting activity of the polypeptide is tested by fluorescence quantitative PCR and indirect immunofluorescence experiment. The results show that the sequence 170849 can significantly inhibit the infection of PEDV.

The application is based on machine learning model, and the polypeptide YYRKWP (168510) with potential is screened through polypeptide virtual screening technology based on the analysis of PEDV Nsp5 protein crystal structure. The sequence of 168510 is artificially synthesized by solid phase, and the polypeptide is screened by using artificially expressed PEDV Nsp5 protein through ELISA experiment. The affinity constant of the polypeptide and the target protein is identified by surface plasmon resonance experiment (SPR). The cytotoxicity of the polypeptide 168510 is tested by CCK-8 kit. The virus infection inhibiting activity of the polypeptide is tested by fluorescence quantitative PCR and indirect immunofluorescence experiment. The results show that the sequence 168510 can significantly inhibit the infection of PEDV.

The invention belongs to the field of antibodies, and particularly relates to an anti-CD47 monoclonal antibody, and discloses a highly variable region sequence of the monoclonal antibody, the anti-CD47 monoclonal antibody provided by the invention has good binding activity, good anticoagulation effect and strong SIRP alpha blocking efficacy; the phagocytosis promoting effect is obvious; forteBio is used for detecting the affinity constant of the antibody, the KD value is lower than 1 * 10 <-11 > nM, and the affinity of the antibody is high. The compound has a relatively strong phagocytic function and shows a relatively good anti-tumor effect.

The invention provides an application of nevermectin in tumor treatment. According to the present invention, the glucosidase II catalytic subunit GANAB can be subjected to targeted inhibition with the affinity constant KD of 0.312 [mu] M, the effect of the 3-site methoxyl demethylation product Norhistidine of the nehistidine on the GANAB is weak, and the affinity constant KD of the Norhistidine is 97.59 [mu] M; neurotetrastin can inhibit GANAB to induce endoplasmic reticulum stress and unfolded protein reaction of tumor stem cells, promote differentiation of the tumor stem cells, induce death of the tumor stem cells and play a role in inhibiting malignant tumors. In a glioblastoma stem cell model, the cytotoxic activity IC50 of the nevermectin is 7.20 + / -2.10 [mu] M, and a mouse in-situ brain tumor formed by glioblastoma stem cells can be significantly reduced after intratumoral injection, indicating that the nevermectin has good anti-tumor stem cell activity.

The present invention relates to the field of biomedicine technology and provides a MSLN single-domain antibody and its application. The amino acid sequence of the MSLN single-domain antibody is shown in SEQ ID No. 1. The MSLN single-domain antibody provided by the present invention has high activity, strong binding force with the antigen, and high affinity, with an affinity constant of 2.52×10 ‑8 M, provides a new antibody and treatment option for ovarian cancer, etc.

A peptide and its sequence that can inhibit PEDV based on virtual screening. This invention utilizes a machine learning model to analyze the S1-CTD region of the PEDV S protein crystal structure. Through virtual peptide screening technology, a peptide sequence with potential affinity for the target protein, WHFNRP (115042), was identified. The 115042 sequence was artificially synthesized in a solid phase, and the peptide was screened using ELISA with artificially expressed PEDV S1 protein. The affinity constant between the peptide and the target protein was identified using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 115042 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was tested using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that the 115042 sequence significantly inhibited PEDV infection.

The invention discloses preparation of an anti-MCR-1 and anti-MCR-2 monoclonal antibody and development and application of a kit of the anti-MCR-1 and anti-MCR-2 monoclonal antibody, and belongs to the technical field of biological detection. The antibody disclosed by the invention can be used for detecting MCR-1 and MCR-2 proteins, and the detection efficiency of polymyxin drug resistance can be properly improved. The screened antibody can be efficiently paired, shows an excellent synergistic effect in a double-antibody sandwich method, and is strong in signal and low in background. Through surface plasmon resonance detection, the affinity constants of the antibody to MCR-1 and MCR-2 proteins reach a nanomole level, high sensitivity of detection is ensured, the detection limit of recombinant proteins can reach 0.01 ng / mL, and the detection limit of bacteria can reach 104 CFU / mL. The whole detection process only needs 10-15 minutes, the operation is simple, professional equipment and training are not needed, and the method is very suitable for on-site rapid screening. The kit is simple in component, low in production cost and easy to produce and popularize on a large scale.

An anti-NY-ESO-1 nanobody and a use thereof, relating to the field of immunology. The anti-NY-ESO-1 nanobody has specific recognition and binding capabilities for the NY-ESO-1 antigen. The nanobody has a minimum affinity constant of 68.1 nM, which shows that the nanobody has highly specific binding activity. It is expected that the nanobody will be used in the treatment of tumors expressing NY-ESO-1, or in diagnostic detection of an NY-ESO-1 protein.

The application provides an aflatoxin B1 antibody and application, and particularly relates to an aflatoxin B1 antibody containing only a heavy chain variable region, a nucleotide coding the antibody, an expression vector carrying the aflatoxin B1 antibody or a nucleotide sequence coding the same. The application screens and prepares an antibody for the aflatoxin B1 from a phage nanobody synthesis library and applies the antibody to detection or identification of the aflatoxin B1. The affinity constant of the antibody is 4.19E-09, the antibody can effectively detect the aflatoxin B1, and can be identified from other common fungal toxins.

The application discloses a detection method for drug screening and characterization based on nano-surface plasmon resonance technology, and belongs to the technical field of antibody protein affinity detection and antibody drug screening and characterization. The detection method is as follows: a NanoSPR chip is coated with a fixed ligand, an analyte to be detected is added, and then sample injection detection is carried out; a specific fitting curve equation is used to obtain a final protein-protein, antigen-antibody, DNA-protein, etc. D kinetic simulation curve, and then a corresponding equilibrium affinity constant K D is calculated. The application firstly applies the nano-surface plasmon resonance technology to the affinity detection of protein-protein, antigen-antibody, DNA-protein, etc., and analyzes the kinetics of the binding process and the dissociation process at the same time, so that the final detection result is very close to the published equilibrium affinity constant K D , which indicates that the method has very high reliability and accuracy, and can be applied to antibody drug screening and characterization.

The present application relates to the technical field of industrial data analysis, in particular to a textile dyeing production quality prediction method based on data recognition, comprising the following steps: extracting dye molecule affinity constant, salt concentration parameter and temperature parameter, solving according to a thermodynamic adsorption model to generate equilibrium adsorption amount distribution data; extracting dye vat replenishment amount, roller pressure and cloth running speed in the continuous pad dyeing color changing production link. In the present application, space for adjusting liquid discharge can be reserved before the pollution peak approaches the processing limit, and single quality prediction can be expanded to comprehensive judgment considering product quality stability, degraded cloth length control, workshop color changing rhythm coordination and back-end processing load balancing, so that it is more beneficial to compress the quality fluctuation range, reduce the impact of invalid liquid discharge, reduce the mutual interference caused by continuous color changing, and improve the response accuracy of production organization to complex working condition changes in actual production.

The invention relates to a kit for detecting a kidney injury molecule 1 by an antibody-based chemiluminescence method and application of the kit. By designing and optimizing an antigen fragment (KIM-1-S, SEQ ID NO: 1) of KIM-1, a recombinant protein is efficiently prepared by utilizing an escherichia coli expression system, and a BALB / c mouse is immunized based on the antigen, so that the kidney injury molecule 1 is detected. And screening to obtain hybridoma cell strains (6G1 and 8E2) capable of stably secreting the anti-KIM-1 monoclonal antibody. The titers of the monoclonal antibody 6G1 and the monoclonal antibody 8E2 in cell supernatant and ascites respectively reach 1: 512000 and 1: 5120000, the affinity constant (Ka) of the monoclonal antibody 6G1 is 2.43 * 10 < 9 > L / mol, and the Ka value of the monoclonal antibody 8E2 is 1.23 * 10 < 9 > L / mol; a double-antibody sandwich magnetic particle chemiluminescence detection kit is designed based on 6G1 and 8E2, so that the detection sensitivity is as low as 15.6 pg / mL. The chemiluminescence detection kit designed by the monoclonal antibody provided by the invention has high specificity, strong affinity and ultra-sensitive detection capability, and is suitable for early diagnosis and curative effect observation of renal injury.